[CAS NO. 1420071-30-2]  Bioymifi

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1420071-30-2]

Store
Catalog
SLK-S7942
Brand
Selleck
CAS
1420071-30-2

DESCRIPTION [1420071-30-2]

Overview

MDLMFCD28118988
Molecular Weight494.32
Molecular FormulaC22H12BrN3O4S
SMILESO=C(NC1=O)C2=C1C=CC(C3=CC=C(O3)/C=C(SC4=N)/C(N4C5=CC=C(C=C5)Br)=O)=C2

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM2.0230 mL10.1149 mL20.2298 mL
5 mM0.4046 mL2.0230 mL4.0460 mL
10 mM0.2023 mL1.0115 mL2.0230 mL
50 mM0.0405 mL0.2023 mL0.4046 mL

Description

Bioymifi, a small-molecule agonist, binds to the extracellular domain(ECD) of DR5 with a Kd of 1.2 μM but showed little binding affinity to the DR4 ECD. It induces DR5 clustering and aggregation, leading to apoptosis.

Targets

DR5 receptor [1]
(Cell-based assay)
1.2 μM(Kd)

In vitro

Bioymifi is able to promote cell death without the need for the Smac mimetic in T98G cells. At a 10 μM concentration, bioymifi induces processing of caspase-3 into smaller fragments. Caspase-8 and the related extrinsic apoptotic pathway are essential for bioymifi-induced cell death. Bioymifi induces DR5-dependent death pathways and is independent of TRAIL. Bioymifi binds the ECD of DR5 with a Kd of 1.2 μM but shows little binding affinity to the DR4 ECD. It has poor solubility in buffer solutions. Bioymifi promotes apoptosis by directly binding to and facilitating aggregation of DR5. When bioymifi reaches micromolar concentration, its capability to aggregate DR5 is strong enough to induce apoptosis in various cancer cells.